Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AS101 Oral Solution in Neovascular AMD
NCT03216538Phase 2Completed
- Sponsor
- Feramda Biopharmaceutical
- Start
- Oct 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AS-101 in neovascular age-related macular degeneration (NVAMD), sponsored by Feramda Biopharmaceutical. Started Oct 2018; status: completed.
02
Drugs
AS-101
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03216538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216538.